William Blair reiterates Outperform on BridgeBio Pharma stock

William Blair has reiterated an "Outperform" rating on BridgeBio Pharma (NASDAQ: BBIO). The firm believes the company is set to launch three more products within a year, beyond the already successful Attruby. William Blair forecasts a potential $4 billion in "de-risked peak sales opportunity" from these three new products. Although the company's attention has been on Attruby, BridgeBio is ready to expand its product pipeline.

The firm cites the company's financial growth as evidence, with revenues increasing by 202% in the past year and gross profit margins reaching 94%. William Blair asserts that analysts and the market are underestimating the clinical potential of these opportunities and that the company's shares are undervalued considering their top-line growth prospects. The firm now views BridgeBio as a core "smidcap biotech holding."